Jose Baselga - Bristol Myers Independent Director

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>BMY</div>
BMY -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Dr. Jose Baselga, M.D. Ph.D., is Independent Director of the Company. Dr. Baselga has served as PhysicianinChief of Memorial SloanKettering Cancer Center since January 2013. He has also served as Professor of Medicine at Weill Cornell Medical College and as Attending Physician, Department of Medicine and member, Human Oncology and Pathogenesis Program at MSKCC since January 2013. Previously, Dr. Baselga served as Chief of Division of Hematology Oncology and Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School from January 2010 to December 2012 and President of the American Association for Cancer Research from 2016 to 2017. He also served in various roles at Vall dHebron University Hospital in Barcelona, Spain, including as Founding Director, Vall dHebron Institute of Oncology from 2007 to 2012 and Director, Division of Medical Oncology, Hematology Radiation Oncology and Founding Director and Chairman, Medical Oncology Service from 1996 to 2010. Dr. Baselga also serves on the Board of Foghorn Therapeutics and Breast International Group. He is a cofounder of Tango Therapeutics. He previously served as a Director of Aura Biosciences, Inc. Dr. Baselga was a Director on the Board of Grail, Inc. until March 2018 and continues to serve as Chairman of its Scientific Advisory Board. Dr. Baselga also sits on the Advisory Boards of Aura Biosciences, Inc., Northern Biologics, Inc., Robert H. Lurie Comprehensive Cancer Center at Northwestern University and Siteman Cancer Center, Washington University at St. Louis. He previously served on the Advisory Board of Juno Therapeutics Inc. until 2018
Age: 57  Director Since 2018      
212 546-4020  www.bms.com
Baselga is an internationally recognized physician scientist who brings over 30 years of oncology experience to the Board.

Management Efficiency

The company has Return on Asset of 0.07 % which means that on every $100 spent on asset it made $0.07 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.17 % implying that it generated $0.17 on every 100 dollars invested.
The company has 25.8 B in debt with debt to equity (D/E) ratio of 159.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Bristol Myers Squibb has Current Ratio of 3.8 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Franklyn PrendergastEli Lilly And Company
Frans HoutenNovartis AG
Ann FudgeNovartis AG
Kevin LoftonGilead Sciences
Shantanu NarayenPfizer
Bruce BurlingtonAstrazeneca PLC
Inge ThulinMerck Company
Michael GreenbergAllergan Plc
Mark McClellanJohnson Johnson
Weiying WangAstrazeneca PLC
Tim JacksonSmithAstrazeneca PLC
Simon DingemansGlaxoSmithKline PLC
David HooverEli Lilly And Company
Ralph AlvarezEli Lilly And Company
Craig ThompsonMerck Company
Carol DavidsonAllergan Plc
Cornelia BargmannAstrazeneca PLC
Eugene WashingtonJohnson Johnson
Robert KidderMerck Company
Dimitri AzarNovartis AG
Deborah DiSanzoAstrazeneca PLC

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 30000 people.Bristol Myers Squibb Company (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 30,000 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice PresidentView
Togo West, Independent DirectorView
Karen Vousden, Independent DirectorView
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics OfficerView
Michael Bonney, DirectorView
Alan Lacy, Independent DirectorView
Robert Bertolini, Independent DirectorView
Jose Baselga, Independent DirectorView
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business OperationsView
Gerald Storch, Independent DirectorView
Louis Schmukler, Senior Vice President, President - Global Product Development and SupplyView
Michael Grobstein, Independent DirectorView
Christopher Boerner, Executive Vice President and Chief Commercial OfficerView
Phyllis Yale, DirectorView
John Elicker, Senior Vice President - Corporate Affairs and Investor RelationsView
David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership TeamView
Anne Nielsen, Senior Vice President Chief Compliance and Ethics OfficerView
Karen Santiago, Senior Vice President, Corporate ControllerView
Rupert Vessey, Executive Vice President Research and Early Development Member of the Leadership TeamView
Giovanni Caforio, Chairman of the Board, Chief Executive OfficerView
Vicki Sato, Lead Independent DirectorView
Emmanuel Blin, Senior Vice President Chief Strategy OfficerView
Nadim Ahmed, Executive Vice President and President - HematologyView
Joseph Caldarella, Senior Vice President Corporate ControllerView
Julia Haller, DirectorView
Laurie Glimcher, Independent DirectorView
Murdo Gordon, Executive Vice President Chief Commercial OfficerView
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. CommitteeView
Joseph Eid, Senior Vice President and Head of Global Medical Affairs Member of the Leadership TeamView
Thomas Lynch, Chief Scientific Officer, Executive Vice PresidentView
Lewis Campbell, Independent DirectorView
Dinesh Paliwal, Independent DirectorView
Theodore Samuels, Independent DirectorView
Samuel Moed, Senior Vice President - Strategic Planning and AnalysisView
Matthew Emmens, Independent DirectorView
Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership TeamView
Sandra Leung, Executive Vice President, General CounselView
Paul Autenried, Chief Information Officer, Senior Vice PresidentView
Samit Hirawat, Executive Vice President Chief Medical Officer, Global Drug Development Member of the Leadership TeamView
Francis Cuss, Executive Vice President Chief Scientific OfficerView
Paul Biondi, Senior Vice President, Head of Strategy & Business DevelopmentView
Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership TeamView
Peter Arduini, Independent DirectorView

Stock Performance Indicators

Did you try this?

Run Theme Ratings Now


Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Eli Lilly And. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page